TickerFacts.

Intensity Therapeutics, Inc. (INTS): Shareholders' Equity

Annual figures by period end, from SEC filings.

$11.88M
As of 2025-12-31
$9.21M
As of 2026-06-30
$13.16M2022-12-31: -$15.10M2023-12-31: $13.16M2024-12-31: $2.92M2025-12-31: $11.88M$11.88M
2022-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$11.88M+307.0%2026-03-27, Balance as of period end
2024-12-31$2.92M-77.8%2026-03-27, Balance as of period end
2023-12-31$13.16Mn/m2025-03-13, Balance as of period end
2022-12-31-$15.10Mn/a2024-03-14, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Intensity Therapeutics, Inc. (INTS)2025-12-31$11.88M+307.0%
MiNK Therapeutics, Inc. (INKT)2025-12-31-$14.23Mn/m
BioAtla, Inc. (BCAB)2025-12-31$36.19M+153.7%
Entera Bio Ltd. (ENTX)2025-12-31$13.10M+62.1%
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$8.10M-18.8%
Outlook Therapeutics, Inc. (OTLK)2025-09-30-$32.19Mn/m
Curis Inc (CRIS)2025-12-31$5.46Mn/m
Dyadic International Inc (DYAI)2025-12-31$1.23M-50.1%
Atara Biotherapeutics, Inc. (ATRA)2025-12-31-$38.50Mn/m

Compare INTS, INKT, BCAB, ENTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗